CONTESSA: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, hormone receptor plus (HR plus ) metastatic breast cancer (MBC) who have previously received a taxane

被引：0

作者：

O'Shaughnessy, Joyce ^{[1
]}

Piccart, Martine ^{[2
]}

Schwartzberg, Lee ^{[3
]}

Cortes, Javier ^{[4
,5
,6
,7
]}

Harbeck, Nadia ^{[8
]}

Im, Seock-Ah ^{[9
]}

Rugo, Hope ^{[10
]}

Untch, Michael ^{[11
]}

Yardley, Denise ^{[12
,13
]}

Bondarenko, Igor ^{[14
]}

Dieras, Veronique ^{[15
]}

Pegram, Mark ^{[16
]}

Kroll, Stew ^{[17
]}

O'Connell, Joseph ^{[17
]}

Vacirca, Jeff ^{[17
]}

Wei, Thomas ^{[17
]}

Tang, Kevin ^{[17
]}

Seidman, Andrew ^{[18
]}

机构：

[1] Baylor Univ, Med Ctr, Texas Oncol, US Oncol, Dallas, TX USA

[2] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium

[3] West Canc Ctr, Memphis, TN USA

[4] IOB Inst Oncol, Quironsalud Grp, Madrid, Spain

[5] Vall dHebron Inst Oncol, Madrid, Spain

[6] IOB Inst Oncol, Quironsalud Grp, Barcelona, Spain

[7] Vall dHebron Inst Oncol, Barcelona, Spain

[8] Univ Munchen LMU, Brustzentrum, Munich, Germany

[9] Seoul Natl Univ Hosp, Seoul, South Korea

[10] Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA

[11] Helios Hosp Berlin Buch, Berlin, Germany

[12] Sarah Cannon Res Inst, Nashville, TN USA

[13] Tennessee Oncol, Nashville, TN USA

[14] Dnipropetrovsk Med Acad, Dnipro, Ukraine

[15] Ctr Eugene Marquis, Rennes, France

[16] Stanford Womens Canc Ctr, Palo Alto, CA USA

[17] Odonate Therapeut Inc, San Diego, CA USA

[18] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

CANCER RESEARCH | 2020年 / 80卷 / 04期

关键词：

D O I：

10.1158/1538-7445.SABCS19-OT1-08-09

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OT1-08-09

引用

页数：3

共 50 条

[41] A phase II study of pembrolizumab in combination with palliative radiotherapy (RT) for hormone receptor-positive (HR plus ) metastatic breast cancer (MBC).
Barroso-Sousa, Romualdo
Krop, Ian E.
Trippa, Lorenzo
Tan-Wasielewski, Zhenying
Li, Tianyu
Osmani, Wafa
Andrews, Chelsea
Dillon, Deborah
Richardson, Edward T.
Winer, Eric P.
Mittendorf, Elizabeth A.
Schoenfeld, Jonathan Daniel
Tolaney, Sara M.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[42] Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases
Lin, Nancy U.
Eierman, Wolfgang
Greil, Richard
Campone, Mario
Kaufman, Bella
Steplewski, Klaudia
Lane, Stephen R.
Zembryki, Denise
Rubin, Stephen D.
Winer, Eric P.
JOURNAL OF NEURO-ONCOLOGY, 2011, 105 (03) : 613 - 620
[43] Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases
Nancy U. Lin
Wolfgang Eierman
Richard Greil
Mario Campone
Bella Kaufman
Klaudia Steplewski
Stephen R. Lane
Denise Zembryki
Stephen D. Rubin
Eric P. Winer
Journal of Neuro-Oncology, 2011, 105 : 613 - 620
[44] Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane (vol 28, pg 3256, 2010)
Sparano
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07) : 947 - 947
[45] Phase II trial of combination therapy with metronomic capecitabine (C) and fulvestrant (F) in the treatment of hormone receptor-positive metastatic breast cancer (HR plus MBC)
Blakely, L. J.
Schwartzberg, L. S.
Wang, G.
Somer, B. G.
Wheeler, B. M.
Stepanski, E. J.
Walker, M.
Johns, A.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[46] The PROCEED trial KCSG BR11-01 phase III multicenter randomized open-label study of irinotecan plus capecitabine versus capecitabine in patients previously treated with anthracycline and taxane for HER2 negative metastatic breast cancer
Park, I. H.
Im, S-A
Jung, K. H.
Sohn, J. H.
Park, Y. H.
Park, K-H
Nam, B-H
Kim, J. H.
Kim, H-J
Lee, S.
Kim, T-Y
Lee, K-H
Kim, S-B
Lee, K. S.
Ro, J.
CANCER RESEARCH, 2017, 77
[47] A phase 2 study of poziotinib in patients with HER2-positive metastatic breast cancer (MBC) who have received prior HER2 regimens for MBC
Lathrop, K.
Lucas, J.
Vacirca, J. L.
Bhat, G.
Choi, M. R.
Naughton, M.
CANCER RESEARCH, 2017, 77
[48] Phase 2 study of abemaciclib plus tamoxifen or abemaciclib alone in women with previously treated hormone receptor-positive (HR+), HER2-metastatic breast cancer
Dieras, V.
Hamilton, E.
Johnston, E. L.
Forrester, T.
Martin, M.
CANCER RESEARCH, 2017, 77
[49] SOPHIA: A phase 3, randomized study of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in the treatment of patients with HER2+metastatic breast cancer
Rugo, H. S.
Pegram, M. D.
Gradishar, W. J.
Cortes, J.
Curigliano, G.
Hong, S.
Wigginton, J. M.
Lechleider, R. J.
Cardoso, F.
CANCER RESEARCH, 2017, 77
[50] A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP
Takano, Toshimi
Tsurutani, Junji
Takahashi, Masato
Yamanaka, Takeharu
Sakai, Kazuko
Ito, Yoshinori
Fukuoka, Junya
Kimura, Hideharu
Kawabata, Hidetaka
Tamura, Kenji
Matsumoto, Koji
Aogi, Kenjiro
Sato, Kazuhiko
Nishio, Kazuto
Nakagawa, Kazuhiko
Saeki, Toshiaki
BREAST, 2018, 40 : 67 - 75

← 1 2 3 4 5 →